首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
【24h】

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.

机译:对永久性前列腺近距离放射疗法治疗的Gleason评分为7-10的前列腺癌患者,高生物有效剂量对生化衰竭和生存结果的影响的多中心分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED). METHODS AND MATERIALS: Six centers provided data on 5,889 permanent prostate brachytherapy patients, of whom 1,078 had Gleason score 7 (n = 845) or Gleason score 8-10 (n = 233) prostate cancer and postimplant dosimetry results available. The median prostate-specific antigen level was 7.5 ng/mL (range, 0.4-300). The median follow-up for censored patients was 46 months (range, 5-130). Short-term hormonal therapy (median duration, 3.9 months) was used in 666 patients (61.8%) and supplemental external beam radiotherapy (EBRT) in 620 (57.5%). The patients were stratified into three BED groups: <200 Gy (n = 645), 200-220 Gy (n = 199), and >220 Gy (n = 234). Biochemical freedom from failure (bFFF) was determined using the Phoenix definition. RESULTS: The 5-year bFFF rate was 80%. The bFFF rate stratified by the three BED groups was 76.4%, 83.5%, and 88.3% (p < 0.001), respectively. Cox regression analysis revealed Gleason score, prostate-specific antigen level, use of hormonal therapy, EBRT, and BED were associated with bFFF (p < 0.001). Freedom from metastasis improved from 92% to 99% with the greatest doses. The overall survival rate at 5 years for the three BED groups for Gleason score 8-10 cancer was 86.6%, 89.4%, and 94.6%, respectively (p = 0.048). CONCLUSION: These data suggest that permanent prostate brachytherapy combined with EBRT and hormonal therapy yields excellent bFFF and survival results in Gleason score 7-10 patients when the delivered BEDs are >220 Gy. These doses can be achieved by a combination of 45-Gy EBRT with a minimal dose received by 90% of the target volume of 120 Gy of (103)Pd or 130 Gy of (125)I.
机译:目的:研究接受永久性前列腺近距离放射治疗的格里森评分为7-10的前列腺癌患者的生化控制率和生存率与生物有效剂量(BED)的关系。方法和材料:六个中心提供了5889例永久性前列腺近距离放射治疗患者的数据,其中有1078例Gleason评分为7(n = 845)或Gleason评分为8-10(n = 233)的前列腺癌和植入后剂量学结果可用。中位前列腺特异性抗原水平为7.5 ng / mL(范围0.4-300)。被检查患者的中位随访时间为46个月(范围:5-130)。 666名患者(61.8%)使用了短期激素疗法(中位时间为3.9个月),而620名患者(57.5%)采用了补充外束放射疗法(EBRT)。将患者分为三个BED组:<200 Gy(n = 645),200-220 Gy(n = 199)和> 220 Gy(n = 234)。使用Phoenix定义确定生化失败的自由度(bFFF)。结果:5年bFFF率为80%。三个BED组的分层bFFF率分别为76.4%,83.5%和88.3%(p <0.001)。 Cox回归分析显示格里森评分,前列腺特异性抗原水平,激素疗法的使用,EBRT和BED与bFFF相关(p <0.001)。使用最大剂量后,转移自由度从92%提高到99%。三个BED组的Gleason评分为8-10的癌症在5年时的总生存率分别为86.6%,89.4%和94.6%(p = 0.048)。结论:这些数据表明,永久性前列腺近距离放射疗法结合EBRT和激素疗法可产生出色的bFFF,当分娩的BED> 220 Gy时,Gleason评分7-10例患者的生存率较高。这些剂量可以通过将45-Gy EBRT与最小剂量(120 Gy的(103)Pd或130 Gy的(125)I)的目标体积的90%结合使用来实现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号